Header Logo

Connection

ULRICH STRYCH to Animals

Back to Details
This is a "connection" page, showing publications ULRICH STRYCH has written about Animals.
ULRICH STRYCH
Connection Strength
0.432
Animals
  1. Generation and Characterization of In Vitro Transcribed mRNA. Methods Mol Biol. 2024; 2786:147-165.
    View in: PubMed
    Score: 0.050
  2. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021 03; 170:71-82.
    View in: PubMed
    Score: 0.041
  3. Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc. Int J Biol Macromol. 2025 Jun; 311(Pt 2):143678.
    View in: PubMed
    Score: 0.014
  4. Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine. Nat Commun. 2025 Apr 07; 16(1):2898.
    View in: PubMed
    Score: 0.014
  5. Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
    View in: PubMed
    Score: 0.013
  6. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.013
  7. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.013
  8. Vaxi-DL: An Artificial Intelligence-Enabled Platform for Vaccine Development. Methods Mol Biol. 2023; 2673:305-316.
    View in: PubMed
    Score: 0.012
  9. Protein A-Nanoluciferase fusion protein for generalized, sensitive detection of immunoglobulin G. Anal Biochem. 2023 01 01; 660:114929.
    View in: PubMed
    Score: 0.012
  10. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines. 2022 10; 21(10):1405-1417.
    View in: PubMed
    Score: 0.011
  11. CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance. Infect Immun. 2022 07 21; 90(7):e0006222.
    View in: PubMed
    Score: 0.011
  12. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
    View in: PubMed
    Score: 0.011
  13. Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. Comput Biol Med. 2022 06; 145:105401.
    View in: PubMed
    Score: 0.011
  14. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
    View in: PubMed
    Score: 0.011
  15. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.011
  16. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.011
  17. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.011
  18. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
    View in: PubMed
    Score: 0.010
  19. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.010
  20. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.010
  21. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.010
  22. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
    View in: PubMed
    Score: 0.010
  23. Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as?a Leishmania Vaccine Candidate. J Pharm Sci. 2020 05; 109(5):1673-1680.
    View in: PubMed
    Score: 0.010
  24. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection. PLoS Negl Trop Dis. 2020 02; 14(2):e0008057.
    View in: PubMed
    Score: 0.010
  25. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.009
  26. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
    View in: PubMed
    Score: 0.008
  27. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
    View in: PubMed
    Score: 0.008
  28. Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
    View in: PubMed
    Score: 0.008
  29. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.008
  30. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.007
  31. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.007
  32. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.007
  33. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Hum Vaccin Immunother. 2016 07 02; 12(7):1707-20.
    View in: PubMed
    Score: 0.007
  34. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003575.
    View in: PubMed
    Score: 0.007
  35. Biophysical characterization of VEGF-aHt DNA aptamer interactions. Int J Biol Macromol. 2013 Jun; 57:69-75.
    View in: PubMed
    Score: 0.006
  36. Rare target enrichment for ultrasensitive PCR detection using cot-rehybridization and duplex-specific nuclease. Anal Biochem. 2012 Feb 01; 421(1):81-5.
    View in: PubMed
    Score: 0.005
  37. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit. 2009 Mar-Apr; 22(2):154-61.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.